Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

Chayama, Kazuaki; Suzuki, Fumitaka; Karino, Yoshiyasu; Kawakami, Yoshiiku; Sato, Ken; Atarashi, Tomofumi; Naganuma, Atsushi; Watanabe, Tsunamasa; Eguchi, Yuichiro; Yoshiji, Hitoshi; Seike, Masataka; Takei, Yoshiyuki; Kato, Koji; Alves, Katia; Burroughs, Margaret; Redman, Rebecca; Pugatch, David; J. Pilot-Matias, Tami; Krishnan, Preethi; K. Oberoi, Rajneet; Xie, Wangang; Kumada, Hiromitsu

doi:10.1007/s00535-017-1391-5

Public

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

Published in Journal of Gastroenterology • Sep 25, 2017

Authors:

Kazuaki Chayama

Fumitaka Suzuki

Yoshiyasu Karino

Abstract

BACKGROUND: The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A inhibitor pibrentasvir (G/P), demonstrated high rates of sustained virologic response (SVR) in phase 2 and 3 studies outside Japan....

Subject

Cirrhosis

Hepatology

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!